FOOD AND DRUG ADMINISTRATION CENTER FOR BIOLOGICS EVALUATION AND RESEARCH

VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE

November 28-29, 2001 Holiday Inn, Bethesda

AGENDA

Wednesday, November 28, 2001

8:30 AM	Session 1, 2, 3 - CLOSED SESSIONS		
12:30 PM	Session 4 - OPEN Session Efficacy Trial Endpoints for Vaccines for the Prevention of Human Papilloma Virus		
12:30	Call to Order, Introductions, Administrative Matters	Dr. Robert S. Daum, Committee Chair	
12:45	Introduction to Session and Presentation of Questions	Dr. Karen Goldenthal, FDA	
1:00	Natural History and Virology	Dr. Beth Unger	
1:45	Clinical Management/Natural History of Cervical Dysplasia and Related Findings	Dr. Edward Wilkinson	
2:30	Break		
2:45	Endpoints Re-introduction of Questions and Q & A	Dr. Karen L. Goldenthal, FDA	
3:30	Open Public Hearing		
4:45	Adjourn for the Day		

This is the final Agenda
3805 A

FOOD AND DRUG ADMINISTRATION CENTER FOR BIOLOGICS EVALUATION AND RESEARCH

VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE

November 28-29, 2001 Holiday Inn, Bethesda

AGENDA

Thursday, November 29, 2001

8:30 AM	Session 4 - Open Session Continued	
8:30	Call to Order	Dr. Robert S. Daum
8:40	Committee Discussion and Recommendations	
12:00 noon	Lunch	
1 PM	Session 5 – Open Session Briefing on Activities in the Laboratory of Bacterial Toxins	
1:00	Organizational Structure and Overview of Research and Regulatory Responsibilities in the Division of Bacterial, Parasitic and Allergenic Products	Dr. Richard Walker, FDA
1:10	Organizational Structure and Overview of Regulatory Responsibilities in the Laboratory of Bacterial Toxins	Dr. Willie Vann, FDA
1:15	Description of Research Activities	Dr. Willie Vann, FDA
1:25	Description of Research Activities	Dr. Michael Schmitt, FDA
1:35	End of Open Sessions	
l:45	Session 6 - CLOSED SESSION	
2:30	End of Closed Session; Adjournment of Meeting	